靶向雷帕霉素靶蛋白（mTOR）的药物会产生由CCN2介导的致纤维化副作用吗？
Do drugs that target mTOR generate CCN2-mediated fibrogenic side effects?
作者信息
Leask Andrew
机构信息
Department of Dentistry, Western University, Dental Sciences Building, London, ON, N6A 5C1, Canada.
出版信息
J Cell Commun Signal. 2019 Sep;13(3):277-278. doi: 10.1007/s12079-019-00520-y. Epub 2019 May 22.
Abstract
mTOR, the target of rapamycin, has been promoted as a potential target for cancers, transplantations and even lung fibrosis. However, paradoxically, targeting mTOR has been reported to result in profibrotic side effects. Some recent publications highlight why this might be.
摘要
雷帕霉素靶蛋白（mTOR）已被推崇为癌症、移植甚至肺纤维化的潜在靶点。然而，矛盾的是，有报道称靶向mTOR会导致促纤维化副作用。最近的一些出版物强调了其中的原因。
相似文献
1
Do drugs that target mTOR generate CCN2-mediated fibrogenic side effects?靶向雷帕霉素靶蛋白（mTOR）的药物会产生由CCN2介导的致纤维化副作用吗？
J Cell Commun Signal. 2019 Sep;13(3):277-278. doi: 10.1007/s12079-019-00520-y. Epub 2019 May 22.
2
The matricellular protein CCN1 enhances TGF-β1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury.基质细胞蛋白CCN1增强成纤维细胞中TGF-β1/SMAD3依赖性促纤维化信号传导，并促进对肺损伤的纤维化反应。
FASEB J. 2016 Jun;30(6):2135-50. doi: 10.1096/fj.201500173. Epub 2016 Feb 16.
3
Single-target RNA interference for the blockade of multiple interacting proinflammatory and profibrotic pathways in cardiac fibroblasts.靶向 RNA 干扰阻断心肌成纤维细胞中多个相互作用的促炎和促纤维化途径。
J Mol Cell Cardiol. 2014 Jan;66:141-56. doi: 10.1016/j.yjmcc.2013.11.004. Epub 2013 Nov 12.
4
CCN3, a key matricellular protein, distinctly inhibits TGFβ1-mediated Smad1/5/8 signalling in human podocyte culture.CCN3是一种关键的基质细胞蛋白，在人足细胞培养中可显著抑制转化生长因子β1（TGFβ1）介导的Smad1/5/8信号传导。
Cell Mol Biol (Noisy-le-grand). 2018 Feb 28;64(3):5-10. doi: 10.14715/cmb/2018.64.3.2.
5
CCN3/CCN2 regulation and the fibrosis of diabetic renal disease.CCN3/CCN2 的调控与糖尿病肾病的纤维化。
J Cell Commun Signal. 2010 Mar;4(1):39-50. doi: 10.1007/s12079-010-0085-z. Epub 2010 Feb 9.
6
Prognostic value of CCN3 in osteosarcoma.CCN3在骨肉瘤中的预后价值。
Clin Cancer Res. 2008 Feb 1;14(3):701-9. doi: 10.1158/1078-0432.CCR-07-0806.
7
Yin and Yang revisited: CCN3 as an anti-fibrotic therapeutic?再探阴阳学说：CCN3能否成为抗纤维化治疗手段？
J Cell Commun Signal. 2015 Mar;9(1):97-8. doi: 10.1007/s12079-015-0281-y. Epub 2015 Feb 22.
8
Co-administration of everolimus and N-acetylcysteine attenuates hepatic stellate cell activation and hepatic fibrosis.依维莫司与N-乙酰半胱氨酸联合使用可减轻肝星状细胞活化和肝纤维化。
Am J Transl Res. 2020 Jun 15;12(6):2627-2639. eCollection 2020.
9
Studying the CCN Proteins in Fibrosis.研究纤维化中的CCN蛋白。
Methods Mol Biol. 2017;1489:423-429. doi: 10.1007/978-1-4939-6430-7_35.
10
Cellular and molecular effects of the mTOR inhibitor everolimus.mTOR抑制剂依维莫司的细胞和分子效应
Clin Sci (Lond). 2015 Nov;129(10):895-914. doi: 10.1042/CS20150149.
本文引用的文献
1
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.一项随机、安慰剂对照研究奥米帕利司（PI3K/mTOR）治疗特发性肺纤维化。
Eur Respir J. 2019 Mar 18;53(3). doi: 10.1183/13993003.01992-2018. Print 2019 Mar.
2
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis.mTORC1/4E-BP1 轴在纤维化过程中代表一个关键的信号节点。
Nat Commun. 2019 Jan 2;10(1):6. doi: 10.1038/s41467-018-07858-8.
3
In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets.体外鉴定与高剂量依维莫司诱导的肺纤维化相关的新转录组和 miRNA 组学特征：寻找新的发病机制标志物和治疗靶点。
Int J Mol Sci. 2018 Apr 20;19(4):1250. doi: 10.3390/ijms19041250.
4
Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation.依维莫司诱导支气管/肺细胞上皮-间质转化（EMT）：移植中剂量何时起关键作用。
J Nephrol. 2016 Dec;29(6):881-891. doi: 10.1007/s40620-016-0295-4. Epub 2016 Mar 29.
5
An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis.一项由研究者主导的依维莫司治疗外科肺活检确诊特发性肺纤维化的研究。
Respirology. 2011 Jul;16(5):776-83. doi: 10.1111/j.1440-1843.2011.01955.x.
Zotero 插件